Literature DB >> 19523754

Side population and cancer stem cells: therapeutic implications.

Lidia Moserle1, Margherita Ghisi, Alberto Amadori, Stefano Indraccolo.   

Abstract

New studies indicate that the side population (SP) and cancer stem cells (CSC) drive and maintain many types of human malignancies. SP and CSC appear to be highly resistant to chemo- and radio-therapy and this knowledge is now reshaping our therapeutic approach to cancer. Several studies have pioneered the possibility of specifically targeting CSC and SP cells by exploiting pathways involved in drug resistance, or forcing these cells to proliferate and differentiate thus converting them into a target of conventional therapies. Moreover, certain cytokines - such as IFN-alpha - appear to modulate SP and stem cell functions, and this associates with remarkable therapeutic activity in animal models. These recent findings underscore the need of a more comprehensive view of the interactions between cytokines and key regulatory pathways in SP and CSC. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523754     DOI: 10.1016/j.canlet.2009.05.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  37 in total

1.  SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

Authors:  J-V Malfuson; L Boutin; D Clay; C Thépenier; C Desterke; F Torossian; B Guerton; A Anginot; T de Revel; J-J Lataillade; M-C Le Bousse-Kerdilès
Journal:  Leukemia       Date:  2013-09-03       Impact factor: 11.528

2.  Endosialin expression in side populations in human sarcoma cell lines.

Authors:  Cecile Rouleau; Jose Sancho; Juanita Campos-Rivera; Beverly A Teicher
Journal:  Oncol Lett       Date:  2011-11-14       Impact factor: 2.967

Review 3.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

Review 4.  Metastatic cancer stem cells: from the concept to therapeutics.

Authors:  Wen-Ting Liao; Ya-Ping Ye; Yong-Jian Deng; Xiu-Wu Bian; Yan-Qing Ding
Journal:  Am J Stem Cells       Date:  2014-09-05

Review 5.  Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among WNT/ß-catenin, Sonic Hedgehog, Notch and Dickkopf-1.

Authors:  Alex Giakoustidis; Dimitrios Giakoustidis; Satvinder Mudan; Argyrios Sklavos; Roger Williams
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

6.  Preliminary screening and identification of stem cell-like sphere clones in a gallbladder cancer cell line GBC-SD.

Authors:  Bao-bing Yin; Shuang-jie Wu; Hua-jie Zong; Bao-jin Ma; Duan Cai
Journal:  J Zhejiang Univ Sci B       Date:  2011-04       Impact factor: 3.066

Review 7.  [Translational approaches in cancer stem cell research].

Authors:  C Mozet; G Wichmann; A Dietz
Journal:  HNO       Date:  2011-09       Impact factor: 1.284

8.  Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.

Authors:  Xiaolong Wei; David Dombkowski; Katia Meirelles; Rafael Pieretti-Vanmarcke; Paul P Szotek; Henry L Chang; Frederic I Preffer; Peter R Mueller; Jose Teixeira; David T MacLaughlin; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-15       Impact factor: 11.205

Review 9.  Cancer stem cells in human digestive tract malignancies.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Morvarid Saeinasab
Journal:  Tumour Biol       Date:  2015-10-07

Review 10.  Cancer stem cells in laryngeal cancer: what we know.

Authors:  A Greco; Maria Ida Rizzo; A De Virgilio; A Gallo; M Fusconi; G Pagliuca; S Martellucci; R Turchetta; M De Vincentiis
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-19       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.